Trial Profile
Administration of Jakafi (Ruxolitinib) to Patients With Previously Untreated High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): A Phase II Clinical Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Apr 2021
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 18 Jun 2020 Status changed from recruiting to completed.
- 17 May 2019 Planned End Date changed from 1 Mar 2021 to 8 Mar 2021.
- 17 May 2019 Planned primary completion date changed from 1 Mar 2021 to 8 Mar 2021.